Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 4/2010

01-07-2010 | Original Article

Cooperative effect of serum 25-hydroxyvitamin D concentration and a polymorphism of transforming growth factor-β1 gene on the prevalence of vertebral fractures in postmenopausal osteoporosis

Authors: Seijiro Mori, Noriyuki Fuku, Yuko Chiba, Fumiaki Tokimura, Takayuki Hosoi, Yoshiyuki Kimbara, Yoshiaki Tamura, Atsushi Araki, Masashi Tanaka, Hideki Ito

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2010

Login to get access

Abstract

A T869→C polymorphism of the transforming growth factor-β1 (TGF-β1) gene is reported to be associated with genetic susceptibility to both osteoporosis and vertebral fractures. A low serum 25-hydroxyvitamin D [25(OH)D] level is known to be associated with a higher risk for hip fracture. This study aimed to assess a possible cooperative effect of the gene polymorphism and vitamin D status on vertebral fracture risk. The prevalence of vertebral fracture in 168 postmenopausal female patients with osteoporosis was analyzed, and its association with the TGF-β1 gene polymorphism and serum 25(OH)D concentration was assessed cross-sectionally. The fracture prevalence increased according to the rank order of the TGF-β1 genotypes CC < CT < TT, as expected. A significant difference was found not only between the CC and TT genotypes (P = 0.005) but also between the CC and CT genotypes (P < 0.05) when the patients with serum 25(OH)D of more than the median value [22 ng/ml (55 nmol/l)] were analyzed. On the other hand, when those with serum 25(OH)D of less than the median value were analyzed, the protective effect of the C allele against the fracture was blunted; statistical significance in the difference of the fracture prevalence was lost between the CC genotype and the other genotypes. These data suggest that vitamin D fulfillment is prerequisite for the TGF-β1 genotype in exerting its full effect on the fracture prevalence.
Literature
1.
go back to reference NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef
2.
go back to reference Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara M, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMed Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara M, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337CrossRefPubMed
3.
4.
go back to reference Albagha OM, Ralston SH (2003) Genetic determinants of susceptibility to osteoporosis. Endocrinol Metab Clin N Am 32:65–81CrossRef Albagha OM, Ralston SH (2003) Genetic determinants of susceptibility to osteoporosis. Endocrinol Metab Clin N Am 32:65–81CrossRef
5.
go back to reference Ralston SH, de Crombrugghe B (2006) Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20:2492–2506CrossRefPubMed Ralston SH, de Crombrugghe B (2006) Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20:2492–2506CrossRefPubMed
6.
go back to reference Hirschhorn JN, Gennari L (2008) Bona fide genetic associations with bone mineral density. N Engl J Med 358:2403–2405CrossRefPubMed Hirschhorn JN, Gennari L (2008) Bona fide genetic associations with bone mineral density. N Engl J Med 358:2403–2405CrossRefPubMed
7.
go back to reference Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF (1996) Estrogen promotes apotosis of murine osteoclast mediated by TGF-β. Nat Med 2:1132–1136CrossRefPubMed Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF (1996) Estrogen promotes apotosis of murine osteoclast mediated by TGF-β. Nat Med 2:1132–1136CrossRefPubMed
8.
go back to reference Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S (1999) Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317–1321CrossRefPubMed Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S (1999) Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317–1321CrossRefPubMed
9.
go back to reference Yamada Y, Hosoi T, Makimoto F, Tanaka H, Seino Y, Ikeda K (1999) Transforming growth factor beta-1 gene polymorphism and bone mineral density in Japanese adolescents. Am J Med 106:477–479CrossRefPubMed Yamada Y, Hosoi T, Makimoto F, Tanaka H, Seino Y, Ikeda K (1999) Transforming growth factor beta-1 gene polymorphism and bone mineral density in Japanese adolescents. Am J Med 106:477–479CrossRefPubMed
10.
go back to reference Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A, Ikeda K (1998) Association of a polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to osteoporosis in Japanese women. J Bone Miner Res 13:1569–1576CrossRefPubMed Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A, Ikeda K (1998) Association of a polymorphism of the transforming growth factor-β1 gene with genetic susceptibility to osteoporosis in Japanese women. J Bone Miner Res 13:1569–1576CrossRefPubMed
11.
go back to reference Yamada Y, Miyauchi A, Takagi Y, Nakauchi K, Miki N, Mizuno M, Harada A (2000) Association of a polymorphism of the transforming growth factor-β1 gene with prevalent vertebral fractures in Japanese women. Am J Med 109:244–247CrossRefPubMed Yamada Y, Miyauchi A, Takagi Y, Nakauchi K, Miki N, Mizuno M, Harada A (2000) Association of a polymorphism of the transforming growth factor-β1 gene with prevalent vertebral fractures in Japanese women. Am J Med 109:244–247CrossRefPubMed
12.
go back to reference Yamada Y, Harada A, Hosoi T, Miyauchi A, Ikeda K, Ohta H, Shiraki M (2000) Association of transforming growth factor-β1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis. J Bone Miner Res 15:415–420CrossRefPubMed Yamada Y, Harada A, Hosoi T, Miyauchi A, Ikeda K, Ohta H, Shiraki M (2000) Association of transforming growth factor-β1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis. J Bone Miner Res 15:415–420CrossRefPubMed
13.
go back to reference Riggs BL (2003) Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis. J Cell Biochem 88:209–215CrossRefPubMed Riggs BL (2003) Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis. J Cell Biochem 88:209–215CrossRefPubMed
14.
go back to reference Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501CrossRefPubMed Lips P (2001) Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477–501CrossRefPubMed
15.
go back to reference Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older US white adults. J Bone Miner Res 23:143–150CrossRefPubMed Looker AC, Mussolino ME (2008) Serum 25-hydroxyvitamin D and hip fracture risk in older US white adults. J Bone Miner Res 23:143–150CrossRefPubMed
16.
go back to reference Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, Lee JS, Jackson RD, Robbins JA, Wu C, Stanczyk FZ, LeBoff MS, Wactawski-Wende J, Sarto G, Ockene J, Cummings SR (2008) Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 149:242–250PubMed Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, Lee JS, Jackson RD, Robbins JA, Wu C, Stanczyk FZ, LeBoff MS, Wactawski-Wende J, Sarto G, Ockene J, Cummings SR (2008) Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 149:242–250PubMed
17.
go back to reference Walsh MC, Hunter GR, Livingstone MB (2006) Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 17:61–67CrossRefPubMed Walsh MC, Hunter GR, Livingstone MB (2006) Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 17:61–67CrossRefPubMed
18.
go back to reference Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996CrossRefPubMed Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996CrossRefPubMed
19.
go back to reference Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M (2005) Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society: guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23:97–104CrossRefPubMed Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M (2005) Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society: guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23:97–104CrossRefPubMed
20.
go back to reference Tzakas P, Wong BY, Logan AG, Rubin LA, Cole DE (2005) Transforming growth factor beta-1 (TGFB1) and peak bone mass: association between intragenic polymorphisms and quantitative ultrasound of the heel. BMC Musculoskelet Disord 6:29CrossRefPubMed Tzakas P, Wong BY, Logan AG, Rubin LA, Cole DE (2005) Transforming growth factor beta-1 (TGFB1) and peak bone mass: association between intragenic polymorphisms and quantitative ultrasound of the heel. BMC Musculoskelet Disord 6:29CrossRefPubMed
21.
go back to reference Bonewald LF (1996) Transforming growth factor-β. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, San Diego, pp 647–659 Bonewald LF (1996) Transforming growth factor-β. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, San Diego, pp 647–659
22.
go back to reference Sterck JG, Klein-Nulend J, Burger EH, Lips P (1996) 1, 25-Dihydroxyvitamin D3-mediated TGF-beta release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiency. J Bone Miner Res 11:367–376CrossRefPubMed Sterck JG, Klein-Nulend J, Burger EH, Lips P (1996) 1, 25-Dihydroxyvitamin D3-mediated TGF-beta release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiency. J Bone Miner Res 11:367–376CrossRefPubMed
23.
go back to reference Finkelman RD, Linkhart TA, Mohan S, Lau KH, Baylink DJ, Bell NH (1991) Vitamin D deficiency causes a selective reduction in deposition of TGF-beta in rat bone: possible mechanism for impaired osteoinduction. Proc Natl Acad Sci USA 88:3657–3660CrossRefPubMed Finkelman RD, Linkhart TA, Mohan S, Lau KH, Baylink DJ, Bell NH (1991) Vitamin D deficiency causes a selective reduction in deposition of TGF-beta in rat bone: possible mechanism for impaired osteoinduction. Proc Natl Acad Sci USA 88:3657–3660CrossRefPubMed
24.
go back to reference Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV (1985) Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature (Lond) 316:701–705CrossRef Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV (1985) Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature (Lond) 316:701–705CrossRef
25.
go back to reference Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S et al (2008) Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone (NY) 42:969–981 Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S et al (2008) Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. Bone (NY) 42:969–981
Metadata
Title
Cooperative effect of serum 25-hydroxyvitamin D concentration and a polymorphism of transforming growth factor-β1 gene on the prevalence of vertebral fractures in postmenopausal osteoporosis
Authors
Seijiro Mori
Noriyuki Fuku
Yuko Chiba
Fumiaki Tokimura
Takayuki Hosoi
Yoshiyuki Kimbara
Yoshiaki Tamura
Atsushi Araki
Masashi Tanaka
Hideki Ito
Publication date
01-07-2010
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 4/2010
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-009-0147-6

Other articles of this Issue 4/2010

Journal of Bone and Mineral Metabolism 4/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.